Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

Table 2 In vitro concentrations of 5-AZA-CdR that eradicate the proliferative potential of leukemic cells

Leukemic cell lines	IC50	Duration of exposure	References
HL 60 (myeloid)	100 μM	1 hour	[59]
Molt-3 (T-cell)	10 μM	1 hour	[59]
RPMI 8392 (B-cell)	10 μM	1 hour	[59]
HL60 leukemic cells	0.05 to 0.1 μM	24 hours	[60]
L1210 leukemic cells	0.075 μM	18 hours	[60]
Molt-3 (T-cell)	about 0.1 μM	24 hours	[59]
HL 60 (myeloid)	about 0.1 μM	24 hours	[59]
RPMI 8392 (B-cell)	about 0.1 μM	24 hours	[59]

1 μM = 228 ng/ml. 5-AZA-CdR, 5-Aza-2′-deoxycytidine; IC50, half maximal inhibitory concentration.

ISSN: 1868-7083